OrganiGram Stock: An Investor Favorite on a Bull Run Again! Why?

OrganiGram Stock

Based on stock performance, OrganiGram Holdings (TSXV:OGI) (OTCQX:OGRMF) ranks as the second-best marijuana stock of 2019. With this in mind, investors might be looking to invest in OrganiGram stock.

There are two reasons in particular that make OrganiGram a stand-out cannabis company. Let’s look at them.

Organigram Stock Reason 1: Costs Per Gram

OrganiGram Holdings is expecting production capacity to come in at 113,000 kg at peak capacity by the fall of 2019. This figure means it is keeping up but isn’t exactly outpacing its larger peers. What it is doing, though, is creating profits where those larger peers aren’t.

According to The Motley Fool:

“While capacity is important to driving revenue, the costs to produce cannabis is key for driving profits.”

OrganiGram is doing this by keeping its costs per gram to cultivate dried flower low. Very low. At only $0.74 CAD/$0.55 USD per gram in Q1, it is the lowest of its peers. For comparison, Aurora Cannabis’s (TSX:ACB) (NYSE:ACB) cost per gram is almost $1 CAD/$0.75 USD.

OrganiGram Holdings can do this because it has “industry-leading yield.” Effectively, OrganiGram obtained an average of 153 grams per harvested plant in Q1 of 2019. This type of yield per plant means the company can make a profit by keeping production costs down.

Capitalize off Cannabis
Sign up now to start receiving our investing insights for FREE!

 

For OrganiGram stock investors, they are getting more bang for their buck… literally.

>> ACB Stock Provides Solid Return in First Quarter, Now What?

OrganiGram Stock Reason 2: International Markets

By now, we all know the huge potential in the Canadian and US markets. But what about capitalizing on Europe too? With two major partnerships overseas, OrganiGram is primed to capitalize on markets that are going to be bigger than the Canadian and US ones.

The markets in question are the European medical cannabis and CBD markets. In recent months, six major European countries have changed their legislation regarding the growth, sale, or consumption of cannabis. These include France, the UK, Spain, Germany, Italy, and the Netherlands–countries considered industry leaders.

Now, according to Consultancy EU:

“With a population of more than double that of the United States and Canada combined, the market is ripe, and the industry has grown more in the last year than the last six combined, according to a new report.”

An estimated worth of €123 billion by 2028 (according to ‘The European Cannabis Report’) means “Europe is set to become the world’s largest legal cannabis market.” Knowing this, OrganiGram stock is in line to reap rewards from this potential because it has two major partnerships.

The first is a partnership with Alpha-cannabis to target the German medical cannabis market. The second is a partnership with Serbia-based Eviana to purchase up to 25% of its hemp-derived CBD oil.

These two key market areas give OrganiGram a foothold into the burgeoning European industry, one it will no doubt evolve with.  

The Takeaway

Organigram stock is close to doubling in value from this period last year. It’s clear to see why it’s on the up. At the time of writing, OGRMF stock is selling for $7.04 USD and is on a bull run (yet again), up 6.08% at the time of writing.

There are several reasons OrganiGram stock is an investor favorite. Those listed above are just two. If you are thinking of investing always take your research as far as you can before you place your money down.

What do you think? Is OrganiGram stock on your radar?

>> Read More OrganiGram News

Featured Image: Canva